aHUS caused by complement dysregulation: new therapies on the horizon.
about
Atypical hemolytic uremic syndromeInsufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapyPre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndromeComplement regulation: physiology and disease relevanceA new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injuryAtypical hemolytic-uremic syndrome: a case report and literature reviewProduction of biologically active complement factor H in therapeutically useful quantitiesEculizumab: a review of its use in atypical haemolytic uraemic syndromePlasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations.Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan.Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndromeFulminant thrombotic microangiopathy in pediatrics: where diagnostic and therapeutic dilemmas meet.Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case.An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children.Thrombotic microangiopathy and associated renal disorders.Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies.Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation.Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab.Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab.Complement disorders and hemolytic uremic syndrome.Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathyCurrent evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome.Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research.Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society.Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission.Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension.Hemolytic uremic syndrome with simultaneous Shiga toxin producing Escherichia coli and complement abnormalitiesSuccess of eculizumab in the treatment of atypical hemolytic uremic syndrome.How I treat refractory thrombotic thrombocytopenic purpura.Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS).Irreversible severe kidney injury and anuria in a 3-month-old girl with atypical haemolytic uraemic syndrome under administration of eculizumab.Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patientsProgress and Trends in Complement TherapeuticsCommon and rare variants associating with serum levels of creatine kinase and lactate dehydrogenase.Overcoming technical challenges when treating atypical hemolytic uremic syndrome with therapeutic plasma exchange.The complement cascade and renal disease.
P2860
Q21202864-0B365D74-6B5F-4C65-A1D7-25A780240A40Q24609286-797CE834-07B0-42AB-866B-A27C33EC0842Q24622189-97F79916-0E73-4C2F-B823-D748C48AF260Q26795441-AF5EE47C-261D-477E-9DE0-2A8EDFDB29CCQ26992169-6F13FE1E-83B9-4AA1-8F80-AB8A3BEDFE2AQ27003863-1CD2F378-2742-4200-A6B3-2DB19268624EQ28300280-187B710A-F982-44A0-AFAB-36DD577DFC47Q28302228-397917D8-6AC3-4C11-91D5-AA0B5BE059EEQ33396013-737DA1E9-07C3-4A03-9922-E9CF3E50F85AQ33396314-FBD04000-C3FC-49ED-9A9A-2C46F87AB0F5Q33396792-732D1B9E-B5C4-4B0A-A0A9-C6FBE0375985Q33400197-D1FC18E0-6445-4E97-AF7B-73C3FD9608DBQ33401621-FACC2E68-E1C5-426E-AE1E-ECBAACC1A82CQ33401628-08857C87-3161-46BB-A233-32ED934F144DQ33402372-FD7FF7DD-15CD-4F9F-8604-4809799F1C8AQ33402784-8875100D-51A4-4EAD-AB85-1A2DE926500CQ33402867-873450F8-3C23-43F9-A8B9-E6D91C30095FQ33403172-5FAEFAE9-5590-4273-AD79-2443CEF44268Q33405726-D00ACB46-6F8F-4368-B770-414A135B2A73Q33405802-88329B16-248A-4310-83F4-30EB809D49A1Q33408788-4E99D78E-0C40-4F7F-B6C2-82C8667AE6A4Q33409030-1BB09C7C-77E2-416C-8ED8-713599713678Q33411009-A6FDCF54-B7F5-4DD3-B8C4-84E2ABF349CFQ33412143-DD553D03-9AE0-4FD8-8F57-049072EC37E8Q33415471-AACA0397-7217-4E36-A05E-F4EB8F064B2DQ33416830-D2ADA983-7135-41C4-8F0B-653D7700F201Q33417375-139D6228-4346-46D4-A42E-5450A00D0E8FQ33418217-DC8AB5E6-FF0D-4B94-BC0B-34D81A9D11EBQ33418560-B257244F-32D7-4697-A19A-50550AAB5E0CQ33418632-F5AA2787-54B5-4A15-8876-B1704D578F11Q33421268-2356CBD1-5625-48B9-B7EE-5485EFDCA68BQ33421669-1D67E6F0-C497-4C83-B839-03EBA0CA3C05Q33424274-A752FB1B-4371-437D-9FFC-72D3EE05C46FQ33426147-C9FBE906-312E-4363-BC9A-387275314DD8Q33429572-0F03FF5A-1003-4F25-9338-9F79638E84C8Q36241014-019E980C-44CD-4C22-A66F-FBB96CF0B4B3Q36479278-C76B0F3C-5DAF-4C23-AEDF-368D4312E779Q36548818-E58958B9-D7A2-440D-B55E-D9CAF5EC4287Q37336644-562AE952-FC24-4C72-8BB6-83F3F2F936FAQ37502706-56907216-4246-4F58-BA87-C257F971B40F
P2860
aHUS caused by complement dysregulation: new therapies on the horizon.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
aHUS caused by complement dysregulation: new therapies on the horizon.
@ast
aHUS caused by complement dysregulation: new therapies on the horizon.
@en
type
label
aHUS caused by complement dysregulation: new therapies on the horizon.
@ast
aHUS caused by complement dysregulation: new therapies on the horizon.
@en
prefLabel
aHUS caused by complement dysregulation: new therapies on the horizon.
@ast
aHUS caused by complement dysregulation: new therapies on the horizon.
@en
P2860
P921
P1433
P1476
aHUS caused by complement dysregulation: new therapies on the horizon.
@en
P2093
Aoife M Waters
Christoph Licht
P2860
P2888
P356
10.1007/S00467-010-1556-4
P577
2010-06-18T00:00:00Z
2011-01-01T00:00:00Z
P5875
P6179
1050560707